By Nigam Arora & Dr. Natasha Arora
The Arora Report typically gives target zones with the buy signals. The first target zone for Ocugen (OCGN) was $7.73 to $8.31. The stock hit $8 before pulling back.
Per the system, all subscribers should have taken full profits and exited the position or taken partial profits. Those who were willing to take the risk for the stock to hit the second target zone would have left a small quantity. Such quantity should have been sold per the system when the stock continued pulling back.
The prior buy zone is no longer valid as this trade is complete.
It is the subscriber’s responsibility to follow the system and book profits. Normally new posts are not done to reduce the number of emails subscribers get because the system works on auto-pilot. Since there is an influx of new subscribers, this post is being done to help new subscribers get used to the system.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
